Chariklia Gouva

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Hiddo J.L. Heerspink, Rajiv Agarwal, George L. Bakris et al. · Nephrology Dialysis Transplantation · 2024 · 77 citations · Full text

Medicine, Nephrology, Pharmacotherapy +16

Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance

Chariklia Gouva, K. Katopodis, Petros Nikolopoulos et al. · Cardiovascular Drugs and Therapy · 2007 · 37 citations

Medicine, Nephrology, Pharmacotherapy +11

PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin

Eleni C. Papavasiliou, Chariklia Gouva, Kostas C. Siamopoulos et al. · Nephrology Dialysis Transplantation · 2006 · 33 citations · Full text

Medicine, Biochemistry, Nephrology +11

Sevelamer Hydrochloride versus Aluminum Hydroxide: Effect on Serum Phosphorus and Lipids in CAPD Patients

K. Katopodis, Emilios Andrikos, Chariklia Gouva et al. · Peritoneal Dialysis International · 2006 · 32 citations

Medicine, Nephrology, Pharmacotherapy +16

Long-Term Treatment With EPO Increases Serum Levels of High-Density Lipoprotein in Patients With CKD

Kostas C. Siamopoulos, Chariklia Gouva, K. Katopodis et al. · American Journal of Kidney Diseases · 2006 · 22 citations · Full text

Medicine, Nephrology, Renal Pathophysiology +6